Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Nasdaq Pharmaceuticals ETF FT (FTXH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family First Trust Portfolios
  • Assets Under Management 4,176,000
  • Market Capitalization, $K 4,176
  • Shares Outstanding, K 200
  • 36-Month Beta 1.29
  • Price/Book 3.74
  • Price/Earnings ttm 32.29
  • Annual Dividend & Yield 0.18 (0.82%)
  • Most Recent Dividend 0.037 on 12/18/18
  • Sectors:

    ETFs - Large Cap

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.73 +7.65%
on 01/29/19
21.24 unch
on 02/15/19
+1.23 (+6.16%)
since 01/15/19
3-Month
17.94 +18.41%
on 12/24/18
22.09 -3.86%
on 12/04/18
unch (+0.01%)
since 11/15/18
52-Week
17.94 +18.41%
on 12/24/18
23.94 -11.27%
on 08/30/18
-0.64 (-2.92%)
since 02/15/18

Most Recent Stories

More News
A Look at Pharma ETFs Post Q4 Results

The strong results but downbeat guidance led to decent returns in the pharma ETFs over the past month.

XPH : 41.70 (+1.04%)
IHE : 152.24 (+1.40%)
PJP : 67.41 (+1.28%)
PPH : 60.96 (+1.20%)
FTXH : 21.24 (+0.87%)
A Look at Pharma ETFs Post Q4 Results

The strong results but downbeat guidance led to decent returns in the pharma ETFs over the past month.

XPH : 41.70 (+1.04%)
IHE : 152.24 (+1.40%)
PJP : 67.41 (+1.28%)
PPH : 60.96 (+1.20%)
FTXH : 21.24 (+0.87%)
Beaten-Down Pharma ETFs to Buy Post Q3 Results

Despite strong results, the broad market sell-off took the sheen from the pharma ETFs over the past month. These funds have a Zacks ETF Rank #2 (Buy), suggesting solid entry point on beaten down prices....

XPH : 41.70 (+1.04%)
MRK : 79.81 (+1.10%)
JNJ : 136.38 (+1.54%)
IHE : 152.24 (+1.40%)
PJP : 67.41 (+1.28%)
PPH : 60.96 (+1.20%)
PFE : 42.40 (+1.02%)
BMY : 51.67 (+1.65%)
FTXH : 21.24 (+0.87%)
Beaten-Down Pharma ETFs to Buy Post Q3 Results

Despite strong results, the broad market sell-off took the sheen from the pharma ETFs over the past month. These funds have a Zacks ETF Rank #2 (Buy), suggesting solid entry point on beaten down prices....

XPH : 41.70 (+1.04%)
MRK : 79.81 (+1.10%)
JNJ : 136.38 (+1.54%)
IHE : 152.24 (+1.40%)
PJP : 67.41 (+1.28%)
PPH : 60.96 (+1.20%)
PFE : 42.40 (+1.02%)
BMY : 51.67 (+1.65%)
FTXH : 21.24 (+0.87%)
ETF Strategies for the Midterm Elections

Investors should focus on some strategies as to which sector should they take positions or which should be avoided if bipartisan government forms.

TAN : 23.23 (-1.65%)
PPA : 59.30 (+1.66%)
GII : 49.42 (+0.75%)
IHE : 152.24 (+1.40%)
XAR : 95.67 (+1.83%)
IGF : 43.12 (+0.82%)
PPH : 60.96 (+1.20%)
KBE : 44.92 (+2.25%)
XPH : 41.70 (+1.04%)
ITA : 208.20 (+2.08%)
PJP : 67.41 (+1.28%)
ICLN : 9.60 (-0.41%)
KRE : 56.04 (+2.17%)
FTXH : 21.24 (+0.87%)
ETF Strategies for the Midterm Elections

Investors should focus on some strategies as to which sector should they take positions or which should be avoided if bipartisan government forms.

TAN : 23.23 (-1.65%)
PPA : 59.30 (+1.66%)
GII : 49.42 (+0.75%)
IHE : 152.24 (+1.40%)
XAR : 95.67 (+1.83%)
IGF : 43.12 (+0.82%)
PPH : 60.96 (+1.20%)
KBE : 44.92 (+2.25%)
XPH : 41.70 (+1.04%)
ITA : 208.20 (+2.08%)
PJP : 67.41 (+1.28%)
ICLN : 9.60 (-0.41%)
KRE : 56.04 (+2.17%)
FTXH : 21.24 (+0.87%)
Pharma & Biotech ETFs Soar on Trump's Drug Plan

Trump's drug plan went in favor of pharma and biotech companies, which caused these ETFs soaring.

XPH : 41.70 (+1.04%)
PBE : 52.83 (+1.48%)
SBIO : 33.92 (+2.02%)
PTH : 82.34 (+1.07%)
PJP : 67.41 (+1.28%)
IHE : 152.24 (+1.40%)
PPH : 60.96 (+1.20%)
GNRX : 22.33 (+1.78%)
PILL : 26.69 (+3.61%)
SPY : 277.37 (+1.09%)
FTXH : 21.24 (+0.87%)
Pharma & Biotech ETFs Soar on Trump's Drug Plan

Trump's drug plan went in favor of pharma and biotech companies, which caused these ETFs soaring.

XPH : 41.70 (+1.04%)
PBE : 52.83 (+1.48%)
SBIO : 33.92 (+2.02%)
PTH : 82.34 (+1.07%)
PJP : 67.41 (+1.28%)
IHE : 152.24 (+1.40%)
PPH : 60.96 (+1.20%)
GNRX : 22.33 (+1.78%)
PILL : 26.69 (+3.61%)
SPY : 277.37 (+1.09%)
FTXH : 21.24 (+0.87%)
Q1 Earnings Drag Pharma ETFs Down

Pharma ETFs saw terrible trading over the past month as mediocre results failed to boost confidence in the space, pushing many funds to 52-week lows.

XPH : 41.70 (+1.04%)
JNJ : 136.38 (+1.54%)
MRK : 79.81 (+1.10%)
PJP : 67.41 (+1.28%)
IHE : 152.24 (+1.40%)
LLY : 122.48 (+1.43%)
PPH : 60.96 (+1.20%)
PFE : 42.40 (+1.02%)
BMY : 51.67 (+1.65%)
FTXH : 21.24 (+0.87%)
Q1 Earnings Drag Pharma ETFs Down

Pharma ETFs saw terrible trading over the past month as mediocre results failed to boost confidence in the space, pushing many funds to 52-week lows.

XPH : 41.70 (+1.04%)
JNJ : 136.38 (+1.54%)
MRK : 79.81 (+1.10%)
PJP : 67.41 (+1.28%)
IHE : 152.24 (+1.40%)
LLY : 122.48 (+1.43%)
PPH : 60.96 (+1.20%)
PFE : 42.40 (+1.02%)
BMY : 51.67 (+1.65%)
FTXH : 21.24 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade FTXH with:

Fund Summary

The First Trust Nasdaq Pharmaceuticals ETF is an exchange-traded fund. The investment objective of the Fund is to seek investment results that correspond generally to the price and yield, before the Fund's fees and expenses, of an index called the Nasdaq US Smart Pharmaceuticals Index. The Fund seeks...

See More

Key Turning Points

2nd Resistance Point 21.29
1st Resistance Point 21.27
Last Price 21.24
1st Support Level 21.19
2nd Support Level 21.14

See More

52-Week High 23.94
Fibonacci 61.8% 21.65
Last Price 21.24
Fibonacci 50% 20.94
Fibonacci 38.2% 20.23
52-Week Low 17.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar